Mani Foroohar
Stock Analyst at Leerink Swann
(2.25)
# 2,694
Out of 4,955 analysts
167
Total ratings
48.89%
Success rate
-6.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Underperform | $18 → $15 | $27.60 | -45.65% | 18 | Aug 22, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $19.72 | -49.29% | 2 | Jul 21, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Market Perform | $37 → $8 | $3.88 | +106.19% | 12 | May 28, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $4.97 | +262.17% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $5.06 | +18.58% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $7.22 | +273.83% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $20.30 | +254.68% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $1.65 | +930.30% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $70.58 | -30.58% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $49.31 | -6.71% | 15 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $10.09 | +118.04% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $53 → $62 | $42.43 | +46.12% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $13.06 | -0.46% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $19.90 | +45.73% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.47 | -26.87% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.96 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $4.16 | +645.19% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.19 | +490.72% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $21.30 | +87.79% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $10.59 | +693.20% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.91 | +140.55% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $16.96 | +354.01% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $462.74 | -69.10% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $7.29 | -17.70% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $54.64 | +39.09% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.95 | +1,648.07% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $2.90 | +589.66% | 6 | Jul 23, 2021 |
Moderna
Aug 22, 2025
Maintains: Underperform
Price Target: $18 → $15
Current: $27.60
Upside: -45.65%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $19.72
Upside: -49.29%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Market Perform
Price Target: $37 → $8
Current: $3.88
Upside: +106.19%
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $4.97
Upside: +262.17%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $5.06
Upside: +18.58%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $7.22
Upside: +273.83%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $20.30
Upside: +254.68%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $1.65
Upside: +930.30%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $70.58
Upside: -30.58%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $49.31
Upside: -6.71%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $10.09
Upside: +118.04%
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $42.43
Upside: +46.12%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $13.06
Upside: -0.46%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $19.90
Upside: +45.73%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.47
Upside: -26.87%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $8.96
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $4.16
Upside: +645.19%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $1.19
Upside: +490.72%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $21.30
Upside: +87.79%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $10.59
Upside: +693.20%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.91
Upside: +140.55%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $16.96
Upside: +354.01%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $462.74
Upside: -69.10%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $7.29
Upside: -17.70%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $54.64
Upside: +39.09%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.95
Upside: +1,648.07%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $2.90
Upside: +589.66%